Cleavage of myelin associated glycoprotein by matrix metalloproteinases

Journal of Neuroimmunology

Volumn 193, Issue 1-2, 2008, Pages 140-148

  Milward, Elizabeth ^a   Kim, Kee Jun ^a,b   Szklarczyk, Arek ^c   Nguyen, Thien ^c   Melli, Giorgia ^c   Nayak, Mamatha ^c   Deshpande, Deepa ^c   Fitzsimmons, Chantel ^a   Hoke, Ahmet ^c   Kerr, Douglas ^c   Griffin, John W ^c   Calabresi, Peter A ^c   Conant, Katherine ^c  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

MAG; MMP; Multiple sclerosis; Myelin; Proteinase

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; METALLOPROTEINASE; MYELIN ASSOCIATED GLYCOPROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CHO CELL; CONTROLLED STUDY; DEMYELINATION; EMBRYO; ENZYME ACTIVITY; MULTIPLE SCLEROSIS; NERVE FIBER GROWTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; RAT; SENSORY NERVE CELL; SPINAL GANGLION;

AMINO ACID SEQUENCE; ANIMALS; AXONS; CHO CELLS; CRICETINAE; CRICETULUS; GANGLIA, SPINAL; HUMANS; MATRIX METALLOPROTEINASE 7; MATRIX METALLOPROTEINASES; MOLECULAR SEQUENCE DATA; MULTIPLE SCLEROSIS; MYELIN-ASSOCIATED GLYCOPROTEIN; NEUROGLIA; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 37749017183     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.11.001     Document Type: Article

References (68)

1. Anthony D.C., Ferguson B., Matyzak M.K., Miller K.M., Esiri M.M., and Perry V.H. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol. Appl. Neurobiol. 23 (1997) 406-415
2. Arquint M., Roder J., Chia L.S., Down J., Wilkinson D., Bayley H., Braun P., and Dunn R. Molecular cloning and primary structure of myelin-associated glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 600-604
3. Avolio C., Giuliani F., Liuzzi G.M., Ruggieri M., Paolicelli D., Riccio P., Livrea P., and Trojano M. Adhesion molecules and matrix metalloproteinases in multiple sclerosis: effects induced by interferon-beta. Brain Res. Bull. 61 (2003) 357-364
4. Avolio C., Filippi M., Tortorella C., Rocca M.A., Ruggieri M., Agosta F., Tomassini V., Pozzilli C., Stecchi S., Giaquinto P., Livrea P., and Trojano M. Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment. Mult. Scler. 11 (2005) 441-446
5. Boz C., Ozmenoglu M., Velioglu S., Kilinc K., Orem A., Alioglu Z., and Altunayoglu V. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin. Neurol. Neurosurg. 108 (2006) 124-128
6. Burke B., Giannoudis A., Corke K.P., Gill D., Wells M., Ziegler-Heitbrock L., and Lewis C.E. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am. J. Pathol. 163 (2003) 1233-1243
7. Campenot R.B. Local control of neurite development by nerve growth factor. Proc. Natl. Acad. Sci. U. S. A. 74 (1977) 4516-4519
8. Chantry A., and Glynn P. A novel metalloproteinase originally isolated from brain myelin membranes is present in many tissues. Biochem. J. 268 (1990) 245-248
9. Clements J.M., Cossins J.A., Wells G.M., Corkill D.J., Helfrich K., Wood L.M., Pigott R., Stabler G., Ward G.A., Gearing A.J., and Miller K.M. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. J. Neuroimmunol. 74 (1997) 85-94
10. Correale J., and Bassani Molinas Mde L. Temporal variations of adhesion molecules and matrix metalloproteinases in the course of MS. J. Neuroimmunol. 140 (2003) 198-209
11. Correale J., Fiol M., and Gilmore W. The risk of relapses in multiple sclerosis during systemic infections. Neurology 67 (2006) 652-659
12. Cossins J.A., Clements J.M., Ford J., Miller K.M., Pigott R., Vos W., Van der Valk P., and De Groot C.J. Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions. Acta Neuropathol. (Berl.) 94 (1997) 590-598
13. Crocker S.J., Whitmire J.K., Frausto R.F., Chertboonmuang P., Soloway P.D., Whitton J.L., and Campbell I.L. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am. J. Pathol. 169 (2006) 2104-2116
14. D'Souza C.A., and Moscarello M.A. Differences in susceptibility of MBP charge isomers to digestion by stromelysin-1 (MMP-3) and release of an immunodominant epitope. Neurochem. Res. 31 (2006) 1045-1054
15. Diaz-Sanchez M., Williams K., DeLuca G.C., and Esiri M.M. Protein co-expression with axonal injury in multiple sclerosis plaques. Acta Neuropathol. (Berl.) 111 (2006) 289-299
16. Dubois B., Masure S., Hurtenbach U., Paemen L., Heremans H., van den Oord J., Sciot R., Meinhardt T., Hammerling G., Opdenakker G., and Arnold B. Resistance of young gelatinase B-deficient mice to experimental autoimmune encephalomyelitis and necrotizing tail lesions. J. Clin. Invest. 104 (1999) 1507-1515
17. Eldridge C.F., Bunge M.B., Bunge R.P., and Wood P.M. Differentiation of axon-related Schwann cells in vitro. I. Ascorbic acid regulates basal lamina assembly and myelin formation. J. Cell Biol. 105 (1987) 1023-1034
18. Esparza J., Kruse M., Lee J., Michaud M., and Madri J.A. MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J. 18 (2004) 1682-1691
19. Fainardi E., Castellazzi M., Bellini T., Manfrinato M.C., Baldi E., Casetta I., Paolino E., Granieri E., and Dallocchio F. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Mult. Scler. 12 (2006) 294-301
20. Gasche Y., Soccal P.M., Kanemitsu M., and Copin J.C. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front. Biosci. 11 (2006) 1289-1301
21. Gijbels K., Masure S., Carton H., and Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J. Neuroimmunol. 41 (1992) 29-34
22. Gijbels K., Proost P., Masure S., Carton H., Billiau A., and Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J. Neurosci. Res. 36 (1993) 432-440
23. Gijbels K., Galardy R.E., and Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J. Clin. Invest. 94 (1994) 2177-2182
24. Graesser D., Mahooti S., Haas T., Davis S., Clark R.B., and Madri J.A. The interrelationship of alpha4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis. Lab. Invest. 78 (1998) 1445-1458
25. Graesser D., Mahooti S., and Madri J.A. Distinct roles for matrix metalloproteinase-2 and alpha4 integrin in autoimmune T cell extravasation and residency in brain parenchyma during experimental autoimmune encephalomyelitis. J. Neuroimmunol. 109 (2000) 121-131
26. Hewson A.K., Smith T., Leonard J.P., and Cuzner M.L. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm. Res. 44 (1995) 345-349
27. Ivaska J., and Heino J. Adhesion receptors and cell invasion: mechanisms of integrin-guided degradation of extracellular matrix. Cell. Mol. Life Sci. 57 (2000) 16-24
28. Jovanova-Nesic K., and Shoenfeld Y. MMP-2, VCAM-1 and NCAM-1 expression in the brain of rats with experimental autoimmune encephalomyelitis as a trigger mechanism for synaptic plasticity and pathology. J. Neuroimmunol. 181 (2006) 112-121
29. Kanesaka T., Mori M., Hattori T., Oki T., and Kuwabara S. Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 77 (2006) 185-188
30. Kieseier B.C., Kiefer R., Clements J.M., Miller K., Wells G.M., Schweitzer T., Gearing A.J., and Hartung H.P. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 121 Pt 1 (1998) 159-166
31. Krekoski C.A., Neubauer D., Graham J.B., and Muir D. Metalloproteinase-dependent predegeneration in vitro enhances axonal regeneration within acellular peripheral nerve grafts. J. Neurosci. 22 (2002) 10408-10415
32. Li C., Tropak M.B., Gerlai R., Clapoff S., Abramow-Newerly W., Trapp B., Peterson A., and Roder J. Myelination in the absence of myelin-associated glycoprotein. Nature 369 (1994) 747-750
33. Li C., Trapp B., Ludwin S., Peterson A., and Roder J. Myelin associated glycoprotein modulates glia-axon contact in vivo. J. Neurosci. Res. 51 (1998) 210-217
34. Liuzzi G.M., Tamborra R., Ventola A., Bisaccia F., Quagliariello E., and Riccio P. Different recognition by clostripain of myelin basic protein in the lipid-free and lipid-bound forms. Biochem. Biophys. Res. Commun. 226 (1996) 566-571
35. Lunn M.P., Crawford T.O., Hughes R.A., Griffin J.W., and Sheikh K.A. Anti-myelin-associated glycoprotein antibodies alter neurofilament spacing. Brain 125 (2002) 904-911
36. Maeda A., and Sobel R.A. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 55 (1996) 300-309
37. McKerracher L., and Winton M.J. Nogo on the go. Neuron 36 (2002) 345-348
38. McKerracher L., David S., Jackson D.L., Kottis V., Dunn R.J., and Braun P.E. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 13 (1994) 805-811
39. Melli G., Keswani S.C., Fischer A., Chen W., and Hoke A. Spatially distinct and functionally independent mechanisms of axonal degeneration in a model of HIV-associated neuropathy. Brain 129 (2006) 1330-1338
40. Moller J.R., Yanagisawa K., Brady R.O., Tourtellotte W.W., and Quarles R.H. Myelin-associated glycoprotein in multiple sclerosis lesions: a quantitative and qualitative analysis. Ann. Neurol. 22 (1987) 469-474
41. Montag D., Giese K.P., Bartsch U., Martini R., Lang Y., Bluthmann H., Karthgasan J., Kirschner D.A., Wintergerst E.S., Nave K.-A., Zielasek J., Toyka K.V., Lipp H.P., and Schachner M. Mice deficient for the myelin-associated glycoprotein show subtle abnormalities in myelin. Neuron 13 (1994) 229-246
42. Morris-Downes M.M., McCormack K., Baker D., Sivaprasad D., Natkunarajah J., and Amor S. Encephalitogenic and immunogenic potential of myelin-associated glycoprotein (MAG), oligodendrocyte-specific glycoprotein (OSP) and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNPase) in ABH and SJL mice. J. Neuroimmunol. 122 (2002) 20-33
43. Nygardas P.T., and Hinkkanen A.E. Up-regulation of MMP-8 and MMP-9 activity in the BALB/c mouse spinal cord correlates with the severity of experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 128 (2002) 245-254
44. Nygardas P.T., Gronberg S.A., Heikkila J., Joronen K., Sorsa T., and Hinkkanen A.E. Treatment of experimental autoimmune encephalomyelitis with a neurotropic alphavirus vector expressing tissue inhibitor of metalloproteinase-2. Scand. J. Immunol. 60 (2004) 372-381
45. Opdenakker G., Nelissen I., and Van Damme J. Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis. Lancet Neurol. 2 (2003) 747-756
46. Ozenci V., Rinaldi L., Teleshova N., Matusevicius D., Kivisakk P., Kouwenhoven M., and Link H. Metalloproteinases and their tissue inhibitors in multiple sclerosis. J. Autoimmun. 12 (1999) 297-303
47. Ozenci V., Kouwenhoven M., Teleshova N., Pashenkov M., Fredrikson S., and Link H. Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J. Neuroimmunol. 108 (2000) 236-243
48. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., and Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am. J. Pathol. 152 (1998) 729-741
49. Paivalainen S., Suokas M., Lahti O., and Heape A. Degraded myelin-associated glycoprotein (dMAG) formation from pure human brain myelin-associated glycoprotein (MAG) is not mediated by calpain or cathepsin L-like activities. J. Neurochem. 84 (2003) 533-545
50. Pedraza L., Owens G.C., Green L.A., and Salzer J.L. The myelin-associated glycoproteins: membrane disposition, evidence of a novel disulfide linkage between immunoglobulin-like domains, and posttranslational palmitylation. J. Cell Biol. 111 (1990) 2651-2661
51. Proost P., Van Damme J., and Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem. Biophys. Res. Commun. 192 (1993) 1175-1181
52. Quarles R.H. Myelin sheaths: glycoproteins involved in their formation, maintenance and degeneration. Cell. Mol. Life Sci. 59 (2002) 1851-1871
53. Quarles R.H. Myelin-associated glycoprotein (MAG): past, present and beyond. J. Neurochem. 100 (2007) 1431-1448
54. Rosenberg G.A., Dencoff J.E., Correa Jr. N., Reiners M., and Ford C.C. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 46 (1996) 1626-1632
55. Sellebjerg F., Madsen H.O., Jensen C.V., Jensen J., and Garred P. CCR5 delta32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J. Neuroimmunol. 102 (2000) 98-106
56. Stebbins J.W., Jaffe H., and Moller J.R. Characterization of myelin-associated glycoprotein (MAG) proteolysis in the human central nervous system. Neurochem. Res. 23 (1998) 1005-1010
57. Tang S., Shen Y.J., De Bellard M.E., Mukhopadhyay G., Salzer J.L., Crocker P.R., and Filbin M.T. Myelin-associated glycoprotein interacts with neurons via a sialic acid binding site at ARG118 and a distinct neurite inhibition site. J. Cell Biol. 138 (1997) 1355-1366
58. Tang S., Woodhall R.W., Shen Y.J., deBellard M.E., Saffell J.L., Doherty P., Walsh F.S., and Filbin M.T. Soluble myelin-associated glycoprotein (MAG) found in vivo inhibits axonal regeneration. Mol. Cell. Neurosci. 9 (1997) 333-346
59. Tang S., Qiu J., Nikulina E., and Filbin M.T. Soluble myelin-associated glycoprotein released from damaged white matter inhibits axonal regeneration. Mol. Cell. Neurosci. 18 (2001) 259-269
60. Teesalu T., Hinkkanen A.E., and Vaheri A. Coordinated induction of extracellular proteolysis systems during experimental autoimmune encephalomyelitis in mice. Am. J. Pathol. 159 (2001) 2227-2237
61. Toft-Hansen H., Nuttall R.K., Edwards D.R., and Owens T. Key metalloproteinases are expressed by specific cell types in experimental autoimmune encephalomyelitis. J. Immunol. 173 (2004) 5209-5218
62. Trapp B.D., Andrews B., Wong A., O'Connell M., and Griffin J.W. Co-localization of the myelin-associated glycoprotein and the microfilament components, F-actin and spectrin, in Schwann cells of myelinated nerve fibres. J. Neurocytol. 18 (1989) 47-60
63. Trojano M., Avolio C., Liuzzi G.M., Ruggieri M., Defazio G., Liguori M., Santacroce M.P., Paolicelli D., Giuliani F., Riccio P., and Livrea P. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS. Neurology 53 (1999) 1402-1408
64. Venkatesh K., Chivatakarn O., Sheu S.S., and Giger R.J. Molecular dissection of the myelin-associated glycoprotein receptor complex reveals cell type-specific mechanisms for neurite outgrowth inhibition. J. Cell Biol. 177 (2007) 393-399
65. Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis. Markers 22 (2006) 235-244
66. Waubant E., Goodkin D.E., Gee L., Bacchetti P., Sloan R., Stewart T., Andersson P.B., Stabler G., and Miller K. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology 53 (1999) 1397-1401
67. Waubant E., Gee L., Miller K., Stabler G., and Goodkin D. IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J. Interferon Cytokine Res. 21 (2001) 181-185
68. Yanagisawa K., Quarles R.H., Johnson D., Brady R.O., and Whitaker J.N. A derivative of myelin-associated glycoprotein in cerebrospinal fluid of normal subjects and patients with neurological disease. Ann. Neurol. 18 (1985) 464-469